Keeping you up to date on recent developments in orthopedics, including: Technology for printing customized neuroprostheses on a 3D bioprinter; AI could expand healing with bioscaffolds; AI detects osteoarthritis years before it develops; 'Bandage' developed to rebuild broken bone.
A Chinese study has discovered that very long-chain fatty acids (VLCFAs) mediate septin organization in pathogenic fungi and that VLCFA biosynthesis represents a new target for controlling pathogenic fungi, which could lead to the development of new fungicides for use in plants and humans.
Australia is famous, among other things, for venomous animals. Its plants, it turns out, are just as hostile. Now, researchers at the University of Queensland have isolated “neurotoxic peptides from the venom of the giant Australian stinging tree,” as they titled their paper. While the tree’s venomous effects were no secret – the authors wrote that it is known for its “remarkably persistent and painful stings upon contact,” which can produce pain flares for weeks – the effect had been attributed to small molecules.
Keeping you up to date on recent developments in oncology, including: Single-cell RNA sequencing may clarify response to chemotherapy; Epigenetic resistance to PARP inhibitors; Researchers eye organ-on-a-chip drug screening model.
BioWorld looks at translational medicine, including: Epigenetic resistance to PARP inhibitors; Arthritis is different disease with antibodies than without.
The European Society for Medical Oncology is slanted toward clinical medicine, and plenary sessions at the ESMO Virtual Congress 2020 featured phase III trials on approved drugs. But there were smaller sessions devoted to basic science as well. At one of those sessions, several researchers shared new insights into metastasis.
Keeping you up to date on recent developments in cardiology, including: Generating 3D heart organoids; Hostility and heart attacks; Virtual screening tool aims to simplify diagnosing pulmonary hypertension.
LONDON - Scenic Biotech BV has signed up Genentech as first partner for its high-throughput platform for identifying genetic modifiers that can suppress or even completely block the effect of a disease-causing mutated gene, as starting points for drug discovery and development. Under the terms of the agreement, Scenic will identify modifiers in undisclosed therapeutic areas, with Genentech, part of the Roche Group, having an option to take multiple targets into development.
Keeping you up to date on recent developments in neurology, including: New smart drug delivery system may help treatment for neurological disorders; Imaging probe developed for Alzheimer's disease; Potential target identified for migraine therapy.
RSS
